Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB-ABBS Cause Product substitution issue? 10 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Product substitution issue have been filed in association with RITUXIMAB-ABBS. This represents 0.2% of all adverse event reports for RITUXIMAB-ABBS.

10
Reports of Product substitution issue with RITUXIMAB-ABBS
0.2%
of all RITUXIMAB-ABBS reports
0
Deaths
2
Hospitalizations

How Dangerous Is Product substitution issue From RITUXIMAB-ABBS?

Of the 10 reports, 2 (20.0%) required hospitalization, and 2 (20.0%) were considered life-threatening.

Is Product substitution issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB-ABBS. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB-ABBS Cause?

Off label use (2,167) Intentional product use issue (273) Dyspnoea (208) Pain (205) Rheumatoid arthritis (202) Intentional dose omission (196) Fatigue (195) Drug ineffective (186) Hypertension (183) Infusion related reaction (183)

What Other Drugs Cause Product substitution issue?

AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (2,832) BUPROPION (1,578) METHYLPHENIDATE (1,408) CLONAZEPAM (1,288) LAMOTRIGINE (979) ALBUTEROL (864) LEVOTHYROXINE (803) DULOXETINE (766) ESTRADIOL (692) SERTRALINE (636)

Which RITUXIMAB-ABBS Alternatives Have Lower Product substitution issue Risk?

RITUXIMAB-ABBS vs RITUXIMAB-ARRX RITUXIMAB-ABBS vs RITUXIMAB-PVVR RITUXIMAB-ABBS vs RIVAROXABAN RITUXIMAB-ABBS vs RIVASTIGMINE RITUXIMAB-ABBS vs RIVOTRIL

Related Pages

RITUXIMAB-ABBS Full Profile All Product substitution issue Reports All Drugs Causing Product substitution issue RITUXIMAB-ABBS Demographics